News

Virginia Governor Glenn Youngkin named BIO’s Governor of the Year

Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award.

BIO’s annual award honors governors for their leadership and commitment to strengthening biotechnology in their state. For over a decade, the award has recognized governors from across the country and both sides of the aisle.

“Investing in biotechnology is investing in Virginia’s future,” said Governor Glenn Youngkin. “As the Commonwealth’s cutting-edge research triangle and network continues to expand, my administration is determined to remain at the forefront of fostering innovation. I am incredibly humbled to receive this award, and I look forward to further solidifying Virginia’s role as a leader in the life sciences industry.”

“It is my honor to recognize Governor Youngkin with BIO’s 2024 Governor of the Year award for his leadership and support of the life sciences in Virginia,” said BIO President and CEO John F. Crowley. “From advancing innovative economic development initiatives for the bioscience ecosystem to investing in cutting-edge life science facilities across the state, Governor Youngkin has worked tirelessly on public policy solutions to help expand opportunities for researchers, entrepreneurs, and patients in Virginia.”

“Virginia’s $8 billion biotechnology industry is thriving because of the steadfast support of our governmental leaders and regional partnerships,” said John Newby, CEO of the Virginia Biotechnology Association. “We thank Governor Youngkin and his administration for making transformational investments in our ecosystem, and for promoting pro-innovation policies that bring life-improving technologies to patients.”

Read more here.

Recent News

01/20/2026

Vibrent Health Joins a Landmark BARDA-Funded Large-Scale Hybrid/Remote Decentralized Clinical Research Study

Vibrent Health, a leading software-as-a-service (SaaS) data company in the field of precision medicine research, is collaborating with Fred Hutch Cancer Center (Fred Hutch) under a $17 million contract awarded through the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV) Consortium. This collaboration drives critical research on correlates of protection (CoPs),

01/18/2026

Gerry Brunk Joins Focused Ultrasound Foundation’s Council

The Foundation is pleased to welcome Gerry Brunk to its Council, a committed group of goodwill ambassadors who partner with the Board of Directors and staff to offer guidance, raise funds, and generate awareness for focused ultrasound technology. Mr. Brunk co-founded Lumira Ventures, a North American healthcare venture capital firm, and serves as managing director in the firm’s Boston office. He has led investments in

01/14/2026

Phlow and Enveda Partner to Advance AI-Driven Chemistry to Accelerate Domestic Pharmaceutical Development and Transform Drug Substance Manufacturing

Phlow Corp., a leading American pharmaceutical contract development and manufacturing organization (CDMO), today announced a major advancement in AI-driven Active Pharmaceutical Ingredient (API) manufacturing process development in collaboration with Enveda, a biotechnology company that learns from life’s chemistry to create better medicines faster. Through a joint pilot program launched last year to rapidly select API